Pfizer clinches the top spot in the competitive 2025 Super Bowl ad race, promising groundbreaking visibility during the big ...

All this negativity, however, does open up an opportunity for investors to buy the stock at a discount. Despite being a top ...

Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...

Pfizer Inc. closed 19.06% short of its 52-week high of $31.54, which the company reached on July 30th.

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...

Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall ...

Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...

Pfizer faces revenue decline from patent expirations, profitability challenges, and bearish technicals. Learn why PFE stock ...

Jefferies analyst Akash Tewari increased the price target for Pfizer (NYSE:PFE) shares from $33.00 to $34.00, while ...

NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with a market capitalization of $17.4 billion, has announced results from its Phase 3 TALAPRO-2 study which show that a combination of ...